Inactivator of the third component of complement as an inhibitor in the properdin pathway
- PMID: 4507613
- PMCID: PMC389672
- DOI: 10.1073/pnas.69.10.2910
Inactivator of the third component of complement as an inhibitor in the properdin pathway
Abstract
Evidence has been obtained that a single protein, known to modulate classical complement activation, also acts as an inhibitor in the properdin or alternate complement pathway. A highly purified inactivator of the third component of complement (C3) from human serum inhibited the proteolysis of Factor B in the properdin system (glycine-rich beta-glycoprotein) by glycine-rich beta-glycoproteinase. The inhibition was by the enzymatic destruction of glycine-rich beta-glycoproteinase activity. The major fragment of C3, C3b, which is the only known substrate of the C3 inactivator, blocked the destruction of glycine-rich beta-glycoproteinase by the C3 inactivator. Thus, in its inhibition of the porperdin pathway, the C3 inactivator destroys both the active form of glycine-rich beta-glycoproteinase and a protein involved in the conversion of the zymogen form of this enzyme (proglycine-rich beta-glycoproteinase) to its active form. The increased susceptibility to infections in a patient homozygous for deficiency of the C3 inactivator demonstrates the biologic significance of this protein.
Similar articles
-
Metabolic studies of the third component of complement and the glycine-rich beta glycoprotein in patients with hypocomplementemia.J Clin Invest. 1974 Jun;53(6):1578-87. doi: 10.1172/JCI107708. J Clin Invest. 1974. PMID: 4830223 Free PMC article.
-
The mechanism of action of the C3b inactivator (conglutinogen-activating factor) on its naturally occurring substrate, the major fragment of the third component of complement (C3b).J Exp Med. 1975 May 1;141(5):1221-6. doi: 10.1084/jem.141.5.1221. J Exp Med. 1975. PMID: 1168693 Free PMC article.
-
Increased susceptibility to infection in a patient with type II essential hypercatabolism of C3.N Engl J Med. 1973 Mar 22;288(12):601-6. doi: 10.1056/NEJM197303222881204. N Engl J Med. 1973. PMID: 4686987 No abstract available.
-
Inhibition of complement-derived enzymes.Ann N Y Acad Sci. 1975 Jun 13;256:441-50. doi: 10.1111/j.1749-6632.1975.tb36070.x. Ann N Y Acad Sci. 1975. PMID: 808993 Review. No abstract available.
-
The properdin pathway: an "alternative activation pathway" or a "critical amplification loop" for C3 and C5 activation?Semin Immunopathol. 2018 Jan;40(1):15-35. doi: 10.1007/s00281-017-0661-x. Epub 2017 Nov 22. Semin Immunopathol. 2018. PMID: 29167939 Review.
Cited by
-
Metabolic studies of the third component of complement and the glycine-rich beta glycoprotein in patients with hypocomplementemia.J Clin Invest. 1974 Jun;53(6):1578-87. doi: 10.1172/JCI107708. J Clin Invest. 1974. PMID: 4830223 Free PMC article.
-
Genetic polymorphism of human factor I (C3b inactivator).Hum Genet. 1985;71(1):45-8. doi: 10.1007/BF00295667. Hum Genet. 1985. PMID: 3897024
-
Genetics of the complement system.J Med Genet. 1975 Dec;12(4):372-7. doi: 10.1136/jmg.12.4.372. J Med Genet. 1975. PMID: 768477 Free PMC article. Review.
-
The influence of C3b inactivator (KAF) concentration on the ability of serum to support complement activation.Clin Exp Immunol. 1975 Jul;21(1):109-14. Clin Exp Immunol. 1975. PMID: 52423 Free PMC article.
-
Restoration by purified C3b inactivator of complement-mediated function in vivo in a patient with C3b inactivator deficiency.J Clin Invest. 1975 Mar;55(3):668-72. doi: 10.1172/JCI107975. J Clin Invest. 1975. PMID: 1117072 Free PMC article.
References
MeSH terms
Substances
LinkOut - more resources
Full Text Sources
Miscellaneous